PRO-C11
A fragment of the N-terminal propeptide of type XI collagen, enabling non-invasive monitoring of cancer associated fibroblast-driven (CAF) extracellular matrix formation and tumor-associated fibrosis in oncology and fibrotic disorders.
Key features and values
- Quantifies N-terminal propeptides of type XI collagen associated with extracellular matrix formation.
- Reflects fibroblast activity and tumor-associated fibrosis.
- Provides a non-invasive measure of extracellular matrix dynamics.
- Supports monitoring of disease progression and response to therapies targeting fibrosis.
- Applicable in research on diseases characterized by aberrant extracellular matrix turnover, such as cancer and fibrotic disorders.
- Facilitates evaluation of interventions aimed at modulating extracellular matrix formation.
- Complements other biomarkers for a comprehensive assessment of tissue remodeling dynamics.
Description
The PRO-C11 biomarker assay measures specific fragments of the N-terminal propeptide of type XI collagen, serving as an indicator of fibroblast-driven extracellular matrix formation and tumor-associated fibrosis. This non-invasive assay provides insights into tissue remodeling processes associated with oncology and fibrotic disorders. By quantifying type XI collagen propeptides, the PRO-C11 assay aids in monitoring disease progression, evaluating treatment efficacy, and understanding the underlying mechanisms of fibrosis and extracellular matrix formation. It serves as a valuable tool in research settings for assessing the dynamics of extracellular matrix turnover and fibroblast activity.
Nordic Bioscience’s assays and services are research use only products and services and do not qualify for medical or diagnostic purposes.
